CClinicalTrials.gg
RecruitingNCT07722091Updated Sep 23, 2026

Intraperitoneal Dexamethasone Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upper Abdominal Surgery

An interventional study of Dexamethasone and Saline (0.9% NaCl) in Hoarseness and Post Operative Complicaiton, sponsored by Fujian Medical University Union Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Fujian Medical University Union Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
584
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether intraoperative spraying of dexamethasone onto the abdominal vagal nerve-rich areas can prevent postoperative hoarseness in patients undergoing elective upper abdominal surgery. The main questions it aims to answer are:

  • Does intraoperative topical dexamethasone spraying reduce the incidence of postoperative hoarseness after upper abdominal surgery?
  • Does postoperative intravenous dexamethasone accelerate recovery in patients who develop hoarseness? Researchers will compare a dexamethasone group (intraoperative spraying of 10 mg dexamethasone in 10 mL normal saline) to a placebo group (intraoperative spraying of 10 mL normal saline alone) to see if dexamethasone reduces the rate of postoperative hoarseness.

Participants will:

  • Undergo voice assessment (GRBAS scale) and voice recording before surgery and daily for 10 days after surgery.
  • Be randomly assigned to receive either dexamethasone or placebo sprayed onto the surgical field at the end of the operation.
  • If hoarseness develops in the placebo group, be randomly assigned again to receive either intravenous dexamethasone (5 mg daily for 3 days) or placebo.
Read the detailed description

The mechanism of postoperative hoarseness remains unclear. It is traditionally attributed to direct injury to the recurrent laryngeal nerve or to endotracheal intubation. However, the surgical field in upper abdominal procedures is remote from the recurrent laryngeal nerve, yet the incidence of hoarseness is higher than in many other surgeries. Preclinical animal experiments by the research group have demonstrated that electrical or thermal stimulation of the subdiaphragmatic vagal nerve can induce vocal cord paralysis, and that immediate topical spraying of dexamethasone onto the affected area significantly reduces this effect. It is hypothesized that thermal injury to vagal nerve fibers in the upper abdomen triggers aberrant signaling through the solitary nucleus to the nucleus ambiguus, ultimately resulting in dysfunction of the recurrent laryngeal nerve.

This trial is designed as a multi-center, prospective, randomized, double-blind, placebo-controlled study. A total of 584 adult patients scheduled for elective gastric, hepatobiliary, or pancreaticoduodenal surgery will be enrolled. At the end of the main surgical procedure and before abdominal closure, the surgeon will spray 10 mg of dexamethasone onto the vagal nerve-rich areas, such as the peritoneum around the esophageal hiatus, the lesser omental sac, and the surface of the hepatoduodenal ligament.

Voice assessments will be conducted daily from postoperative day 1 through day 10 using the GRBAS scale by a trained evaluator blinded to group assignment. Patients will also undergo voice acoustic recording for Praat analysis. Those in the placebo group who develop hoarseness will be re-randomized to receive either intravenous dexamethasone 5 mg or placebo daily for 3 days.

02

Conditions studied

  • Hoarseness
  • Post Operative Complicaiton

Browse trials for

Keywords

  • Dexamethasone
  • Postoperative Hoarseness
  • Upper Abdominal Surgery
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 to 75 years, both sexes.
  • Elective abdominal surgery (including gastric, hepatobiliary, and pancreaticoduodenal surgery) under general anesthesia.
  • American Society of Anesthesiologists (ASA) physical status classification I-III.
  • Preoperative GRBAS Grade (G) score = 0 (no hoarseness).
  • Signed written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Need for systemic glucocorticoid therapy during hospitalization for other reasons.
  • Pre-existing hoarseness, vocal cord paralysis, or organic vocal cord lesions.
  • History of neck surgery, neck radiotherapy, or laryngeal surgery.
  • Known allergy to dexamethasone or other glucocorticoids.
  • Active peptic ulcer or gastrointestinal bleeding within 6 months prior to enrollment.
  • Uncontrolled diabetes mellitus or severe active infection.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
584 participants (estimated)

Study arms

  • Experimental
    Dexamethasone Prophylaxis Group

    At the end of surgery before abdominal closure, 10 mg dexamethasone diluted in 10 mL normal saline is sprayed onto the vagal nerve-rich areas: peritoneum around the esophageal hiatus, lesser omental sac, and surface of the hepatoduodenal ligament. Voice assessed daily (GRBAS scale + Praat recording) from postoperative day 1-10.

    Drug: Dexamethasone

  • Placebo comparator
    Placebo Control Group

    At the end of surgery before abdominal closure, 10 mL normal saline alone is sprayed onto the same vagal nerve-rich areas. Voice assessed daily (GRBAS scale + Praat recording) from postoperative day 1-10. Patients who develop hoarseness (GRBAS Grade ≥2) are re-randomized to receive intravenous dexamethasone 5 mg or placebo daily for 3 days.

    Drug: Saline (0.9% NaCl)

Interventions

  • DrugDexamethasone

    Dexamethasone 10 mg diluted in 10 mL normal saline, sprayed topically onto the vagal nerve-rich areas (esophageal hiatus, lesser omental sac, hepatoduodenal ligament) once at the end of surgery before abdominal closure.

  • DrugSaline (0.9% NaCl)

    10 mL normal saline sprayed topically onto the same vagal nerve-rich areas once at the end of surgery before abdominal closure. Patients in the placebo group who develop hoarseness (GRBAS Grade ≥ 2) will be re-randomized to receive intravenous dexamethasone 5 mg daily or placebo for 3 days.

05

What researchers measure

Primary outcomes

  1. Incidence of postoperative hoarseness within 10 days

    The proportion of patients with a GRBAS (Grade, Roughness, Breathiness, Asthenia, Strain) Grade (G) score ≥ 2 at any time point from postoperative day 1 to day 10.

    Time frame: Postoperative day 1 to day 10.

Secondary outcomes

  1. Time to recovery from hoarseness

    Time frame: From first diagnosis of hoarseness (GRBAS G ≥2) to recovery of voice (GRBAS G <2), assessed up to postoperative day 10.

  2. Change in objective voice acoustic parameters measured by Praat software

    Voice samples are recorded using the same professional recording device with the participant producing a sustained vowel /a:/ for at least 5 seconds (sampling rate 44.1 kHz or 48 kHz, mono, WAV format). The recorded samples are analyzed using Praat software (University of Amsterdam) to extract the following parameters: Jitter (local, %), Fundamental Frequency (F0, Hz), and Harmonics-to-Noise Ratio (HNR, dB). The change in each parameter from baseline will be reported for each group.

    Time frame: Postoperative day 1 to day 10.

  3. Change in Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale subscores over time

    The GRBAS (Grade, Roughness, Breathiness, Asthenia, Strain) scale is a perceptual voice assessment tool. For this study, only the Grade (G) subscore is measured. The G subscore assesses overall hoarseness severity on a 0-3 scale (0=normal, 1=mild, 2=moderate, 3=severe), with higher scores indicating worse voice quality. The G subscore is assessed daily from postoperative day 1 through day 10 and compared between groups to evaluate the trajectory of voice changes. The other four dimensions (R, B, A, S) are not formally scored in this study.

    Time frame: Postoperative day 1 to day 10.

06

Study locations

1 of 4 sites recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian, China
    Not yet recruiting
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, Fujian, China
    Not yet recruiting
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07722091
Lead sponsor
Fujian Medical University Union Hospital
Collaborators
The Second Affiliated Hospital of Fujian Medical University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, The First Affiliated Hospital of Nanchang University
Responsible party
shikaige (Department of anesthesiology, Fujian Medical University Union Hospital) — Principal investigator
First posted
Jul 23, 2026
Start date
Jul 27, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

KAIGE SHI
Contact
shikg2001@163.com
+86-18259992395
ZHONGMENG LAI
principal investigator · Fujian Medical University Union Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion